Short Interest in Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Rises By 25.1%

Neuren Pharmaceuticals Limited (OTCMKTS:NURPFGet Free Report) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 1,178,500 shares, an increase of 25.1% from the January 31st total of 941,700 shares. Based on an average daily trading volume, of 28,200 shares, the short-interest ratio is currently 41.8 days.

Neuren Pharmaceuticals Stock Performance

Shares of Neuren Pharmaceuticals stock remained flat at C$12.00 during trading hours on Monday. The business’s 50-day simple moving average is C$15.02 and its 200 day simple moving average is C$10.82. Neuren Pharmaceuticals has a fifty-two week low of C$5.20 and a fifty-two week high of C$17.21.

Neuren Pharmaceuticals Company Profile

(Get Free Report)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome.

Read More

Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.